CAR⁺ T lymphocytes control tumor growth in vivo. Activated CD3⁺ lymphocytes expressing CAR46ζ or CAR46/28ζ, or control T lymphocytes (5 × 10⁶ cells) were injected intraperitoneally into SCID mice bearing κ⁺ Daudi cells (0.5 × 10⁶ cells) labeled with FFLuc gene. No exogenous cytokines were injected into the mice. Day 0 is the day of adoptive transfer of T cells, 10 to 11 days after tumor implant. Tumor growth was monitored using an in vivo imaging system (Xenogen-IVIS Imaging System). Panels A illustrates that tumor growth measured as intensity of the signal (p/s/cm²/sr) was significantly greater in mice receiving control T cells (top panels) by day 25 after T-cell infusion compared to mice receiving CAR46ζ⁺ T lymphocytes (middle panels) or CAR46/28ζ⁺ T cells (bottom panels). Panel B illustrates the mean ± SD of 6 mice/group (P < .001). Panel C compares outcomes in mice bearing κ⁺ Daudi cells labeled with FFLuc gene and treated with either CAR46ζ⁺ or CAR46/28ζ⁺ T cells and receiving intraperitoneal injections of human immunoglobulins 3 times a week or no treatment. Tumor growth was monitored using an in vivo imaging system (Xenogen-IVIS Imaging System). Data are results of 5 mice/group.